Comprehensive Case Challenges in MASH

Target Audience

The educational design of this activity addresses the needs of gastroenterology and hepatology specialists (MDs, nurse practitioners [NPs], physician associates [PAs], and other healthcare providers) involved in the management of patients with metabolic-associated steatohepatitis (MASH).

Program Overview

With the recent change in terminology to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) and the new cardiometabolic criteria, clinical practice has shifted to incorporate screening of more patients for MASLD/MASH. Employing noninvasive tests (NITs) is essential to identifying patients at high risk for MASH and further disease progression, as well as for selecting patients for the first-ever approved MASH therapy, resmetirom. Cardiometabolic comorbidities are common in these patients, and clinicians must be prepared to manage them, often using glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In this case-based symposium, learners will be divided into teams and will compete to correctly answer clinical decision questions within each case. Each team will be led by our expert faculty, Drs. Vlad Ratziu and Rohit Loomba, with the didactic content presented as an explanation of the correct answer to each question. Topics covered will include nuances of diagnosis and staging using NITs, selecting candidates for resmetirom, and optimal management strategies, such as GLP-1 RAs, for the management of common cardiometabolic comorbidities. Join us for this fun, exciting, and competitive program and see if you have what it takes to win!

Educational Objectives

After completing this activity, the participant should be better able to:

1. Identify noninvasive tools that optimize diagnosis, staging, and monitoring of MASH
2. Develop treatment plans that incorporate recently approved and available therapies that target MASH and comorbid metabolic conditions
3. Describe recent advances and ongoing research in MASH diagnostics and pharmacologic treatment options

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education

Integritas designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live meeting and complete the posttest and program evaluation.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Rohit Loomba, MD, MHSc: Consulting Fees (e.g., advisory boards): 89bio, Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse Bio, Inipharm, Intercept, Inventiva, Ionis, Janssen, Lipidio, Madrigal Pharmaceuticals, Merck, NeuroBo, Novo Nordisk, Pfizer, Sagimet Biosciences, Takeda, Terns Pharmaceuticals, and Viking Therapeutics; Contracted Research: His institution received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals; Ownership Interest: Stock Options (or other ownership interest excluding diversified mutual funds): Sagimet Biosciences; Other: Ownership: Co-founder of LipoNexus Inc.

Vlad Ratziu, MD: Consulting Fees (e.g., advisory boards): 89Bio, AstraZeneca, Akero, Boehringer Ingelheim, Eccogene, Madrigal Pharmaceuticals, Novo Nordisk, Sagimet Biosciences; Research Grant (to institution): Gilead, Intercept, MSD

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.